Safety of rivaroxaban in patients with non-valvular atrial fibrillation to prevent stroke and systemic embolism
Phase of Trial: Phase IV
Latest Information Update: 20 May 2015
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Embolism; Stroke
- Focus Adverse reactions
- 20 May 2015 New trial record
- 15 May 2015 Results presented at the American Geriatrics Society 2015 Annual Scientific Meeting, according to a Janssen Pharmaceuticals media release.
- 15 May 2015 Results published in a Janssen Pharmaceuticals media release.